Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

Wolf Popper LLP is investigating potential securities claims on behalf of Xenon Pharmaceuticals investors following a significant stock price decline. On September 17, 2026, Xenon announced a voluntary pause in new patient enrollment in its MDD and bipolar depression clinical studies due to neuropsychiatric adverse events. The announcement triggered a 30.7% stock price drop, falling from approximately $57.35 to $39.75 per share on heavy trading volume.